Photo from Dana-Farber’s Breast Oncology Center/X
Feb 15, 2024, 18:29
The MARGOT is optimizing preoperative therapy for Stage II-III HER2+ breast cancer – Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X/Twitter:
”The MARGOT study led by Dana-Farber’s Breast Oncology Center and Translational Breast Cancer Research Consortium is optimizing preoperative therapy for Stage II-III HER2+ breast cancer, comparing paclitaxel/margetuximab/pertuzumab to paclitaxel/trastuzumab/pertuzumab. For more information call 877-338-7425 or visit the website.”